DCM
RGC icon

Discovery Capital Management’s Regencell Bioscience RGC Stock Holding History

Discovery Capital Management’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-46,166
Closed -$713K – 108
2025
Q3 		$713K Buy
+46,166
New +$662K 0.04% 79

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Discovery Capital Management's RGC Position: Q4 2025 in Review

Discovery Capital Management sold out of Regencell Bioscience (RGC) in Q4 2025, closing a stake of 46,166 shares — an estimated $713K sold.

Discovery Capital Management first reported a position in RGC in Q3 2025 and held it in 1 quarter. The position peaked at $713K in Q3 2025. 17 funds tracked by Wall St. Rank hold RGC as of Q4 2025.

  • Discovery Capital Management reported no remaining Regencell Bioscience position as of Q4 2025 after selling out during the quarter.
  • Discovery Capital Management sold 46,166 Regencell Bioscience shares in Q4 2025, an estimated $713K.
  • Discovery Capital Management first reported a position in Regencell Bioscience in Q3 2025 and held it in 1 quarter.
  • Discovery Capital Management's Regencell Bioscience position peaked at $713K in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Regencell Bioscience as of Q4 2025.

Based on Discovery Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.